Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Next Previous
Trial Profile

Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUTO 1 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Burkitt's lymphoma; Haematological malignancies
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CARPALL

    • Most Recent Events

    • 07 Dec 2019 Results published in Autolus Therapeutics Media Release
    • 06 Nov 2019 Results (n=17) released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Sep 2019 According to an Autolus media release, results from the study have been published in the journal Nature Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top